Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 2
1947 3
1948 2
1949 2
1953 3
1955 2
1957 2
1958 2
1960 1
1961 2
1962 4
1963 4
1964 3
1965 7
1966 13
1967 13
1968 12
1969 15
1970 17
1971 16
1972 30
1973 27
1974 22
1975 26
1976 31
1977 26
1978 24
1979 14
1980 22
1981 28
1982 31
1983 35
1984 40
1985 61
1986 61
1987 55
1988 93
1989 121
1990 181
1991 237
1992 281
1993 353
1994 262
1995 224
1996 211
1997 234
1998 293
1999 302
2000 318
2001 284
2002 258
2003 276
2004 270
2005 311
2006 314
2007 342
2008 378
2009 397
2010 388
2011 425
2012 419
2013 433
2014 407
2015 307
2016 229
2017 235
2018 264
2019 281
2020 295
2021 247
2022 177
2023 81
2024 69

Text availability

Article attribute

Article type

Publication date

Search Results

10,068 results

Results by year

Filters applied: . Clear all
Page 1
Brimonidine.
Bakheit AH, Alomar AM, Darwish H, Alkahtani HM. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2023;48:1-37. doi: 10.1016/bs.podrm.2022.11.001. Epub 2023 Feb 24. Profiles Drug Subst Excip Relat Methodol. 2023. PMID: 37061271
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
10,068 results
You have reached the last available page of results. Please see the User Guide for more information.